Medication info
EmpagroMet Sustained-release Tablet 25/1000 mg (Empagliflozin, Metformin)

EmpagroMet Sustained-release Tablet 25/1000 mg (Empagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›25mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Dong-A ST Co., Ltd.
Appearance
Light yellow, biconvex, oval-shaped sustained-release film-coated tablet
Packaging
30 tablets / bottle
Approval status
Active

MFDS item code 202501723 · Approved 2025.07.09 · Insurance code 642507900

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken once daily in the evening with a meal. To reduce gastrointestinal adverse effects associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take one tablet of this drug 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this drug 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To maintain its extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. This drug may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in their stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial dose when taking this drug is a total daily dose of empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching to this drug from combination therapy with empagliflozin and metformin should receive their current doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted as appropriate. ⦁ When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). Special Populations Renal Impairment Because dose adjustment according to renal function is necessary, assessment of renal function is recommended before starting treatment with this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2], this drug may be used with metformin hydrochloride dose adjustment as follows, if it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this drug should be discontinued immediately. Elderly Patients In patients aged 75 years and older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Dong-A ST Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Abnormal blood sugar control in adult patients with type 2 diabetes
  • cardiovascular disease
View approved original text

This medication is used to improve blood sugar control in adult patients with type 2 diabetes who are also following a diet and exercise regimen. It is particularly suitable for those whose blood sugar is not adequately controlled, and should be taken with caution according to clinical trial information in cases of concomitant cardiovascular disease. This medication contributes to improving patient health by assisting in blood sugar management.

How to take

Adult dose

For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken once daily in the evening with a meal. To reduce gastrointestinal adverse effects associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take one tablet of this drug 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this drug 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To maintain its extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. This drug may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in their stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial dose when taking this drug is a total daily dose of empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching to this drug from combination therapy with empagliflozin and metformin should receive their current doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted as appropriate. ⦁ When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). Special Populations Renal Impairment Because dose adjustment according to renal function is necessary, assessment of renal function is recommended before starting treatment with this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2], this drug may be used with metformin hydrochloride dose adjustment as follows, if it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this drug should be discontinued immediately. Elderly Patients In patients aged 75 years and older, renal function and the risk of volume depletion should be considered.

Precautions

This medication can cause a rare side effect known as severe lactic acidosis, so if this symptom occurs, medical professionals should be informed immediately. There is a risk of hypoglycemia when used with other diabetes treatments, so caution is required. It should not be used in patients with poor kidney function or those with acute kidney issues. This medication is not indicated for patients with type 1 diabetes or certain metabolic acidosis conditions. It should be discontinued for a certain period prior to and after surgery, and can be resumed once kidney function is normalized. It is not recommended for women who are pregnant or could become pregnant. This medication may increase the risk of genital infections and urinary tract infections, so immediate treatment should be sought if infection symptoms appear. Vitamin B12 levels may decrease, so regular blood tests are recommended to monitor status. Patients at risk of fluid loss or dehydration should have blood pressure and fluid status monitored regularly. Alcohol consumption may increase the risk of side effects from this medication, so it should be avoided. This medication should not be crushed or chewed; it must be swallowed whole, and the tablet shell may appear in feces, which is normal. Elderly patients may have an increased risk of reduced kidney function, so kidney function testing is needed before starting treatment and should be monitored regularly. There may be interactions with other medications, so any concurrent medications should be disclosed to healthcare professionals. Blood sugar control should be monitored regularly while taking this medication, and medical consultation should occur if abnormal symptoms arise.

Side effects

  • lactic acidosis
  • hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased and deficiency of vitamin B12
  • ketosis
  • nausea
  • vomiting
  • diarrhea
Show 116 more
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • dysgeusia
  • pruritus
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • elevated blood creatinine
  • decreased glomerular filtration rate
  • vaginismus
  • vulvitis
  • balanitis
  • perineal necrosis
  • decreased fluid volume
  • hypotension
  • dehydration
  • low blood pressure
  • decreased blood volume
  • orthostatic hypotension
  • syncope
  • interstitial nephritis
  • headache
  • dizziness
  • cerebral infarction
  • stroke
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • asthenia
  • chest discomfort
  • chest pain
  • ankle fracture
  • lateral epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • angina pectoris
  • unstable angina
  • insomnia
  • anxiety
  • weight loss
  • weight gain
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid mass
  • vulvar pruritus
  • genital pruritus
  • diabetic foot
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • urinary stones
  • acute kidney injury
  • chronic kidney disease
  • hematuria
  • overactive bladder
  • renal mass
  • urinary retention
  • urinary pain
  • abnormal urine
  • cervicitis
  • benign prostatic hyperplasia
  • erectile dysfunction
  • atrophic vaginitis
  • cervical dysplasia
  • vaginal discharge
  • hyperglycemia
  • hyponatremia
  • dyslipidemia
  • hypercholesterolemia
  • vitamin D deficiency
  • glaucoma
  • pathological myopia
  • retinal detachment
  • retinal vein occlusion
  • serous retinal detachment
  • dry eyes
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • ocular discomfort
  • eye congestion
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • effort-related dyspnea
  • productive cough
  • allergic rhinitis
  • retained sputum
  • otalgia
  • positional vertigo
  • dizziness
  • tachycardia
  • palpitations
  • arteriosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral artery occlusive disease
  • unstable angina
  • insomnia
  • depression
  • sleep disorder

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to protect it from air and moisture. It should also be kept at room temperature, between 1 to 30 degrees Celsius, avoiding excessively hot or cold places.

Appearance and packaging

Appearance

Light yellow, biconvex, oval-shaped sustained-release film-coated tablet

Package unit

30 tablets / bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.